Autophagy Protects Renal Tubular Cells Against Ischemia / Reperfusion Injury in a Time-dependent Manner
Overview
Cell Biology
Pharmacology
Affiliations
Background/aims: Autophagy is a dynamic catabolic process that maintains cellular homeostasis. Whether it plays a role in promoting cell survival or cell death in the process of renal ischemia/reperfusion (I/R) remains controversial, partly because renal autophagy is usually examined at a certain time point. Therefore, monitoring of the whole time course of autophagy and apoptosis may help better understand the role of autophagy in renal I/R.
Methods: Autophagy and apoptosis were detected after mice were subjected to bilateral renal ischemia followed by 0-h to 7-day reperfusion, exposure of TCMK-1 cells to 24-h hypoxia, and 2 to 24-h reoxygenation. The effect of autophagy on apoptosis was assessed in the presence of autophagy inhibitor 3-methyladenine (3-MA) and autophagy activator rapamycin.
Results: Earlier than apoptosis, autophagy increased from 2-h reperfusion, reached the maximum at day 2, and then began declining from day 3 when renal damage had nearly recovered to normal. Exposure to 24-h hypoxia induced autophagy markedly, but it decreased drastically after 4 and 8-h reoxygenation, which was accompanied with increased cell apoptosis. Inhibition of autophagy with 3-MA increased the apoptosis of renal tubular cells during I/R in vivo and hypoxia/reoxygenation (H/R) in vitro. In contrast, activation of autophagy by rapamycin significantly alleviated renal tissue damage and tubular cell apoptosis in the two models.
Conclusion: Autophagy was induced in a time-dependent manner and occurred earlier than the onset of cell apoptosis as an early response that played a renoprotective role during renal I/R and cell H/R. Up-regulation of autophagy may prove to be a potential strategy for the treatment of acute kidney injury.
Kaur H, Kamboj K, Naik S, Kumar V, Yadav A Front Med (Lausanne). 2024; 11:1412561.
PMID: 39219798 PMC: 7616407. DOI: 10.3389/fmed.2024.1412561.
Wang Y, Song D, Tang L J Inflamm Res. 2023; 16:1457-1469.
PMID: 37042016 PMC: 10083013. DOI: 10.2147/JIR.S402290.
Ma M, Li H, Yin S, Lin T, Song T Cell Mol Biol Lett. 2023; 28(1):20.
PMID: 36890442 PMC: 9997008. DOI: 10.1186/s11658-023-00430-3.
Therapeutic potential of artemisinin and its derivatives in managing kidney diseases.
Jin Q, Liu T, Chen D, Yang L, Mao H, Ma F Front Pharmacol. 2023; 14:1097206.
PMID: 36874000 PMC: 9974673. DOI: 10.3389/fphar.2023.1097206.
Is the proximal tubule the focus of tubulointerstitial fibrosis?.
Peng Z, Wang H, Zheng J, Wang J, Xiang Y, Liu C Heliyon. 2023; 9(2):e13508.
PMID: 36846656 PMC: 9950842. DOI: 10.1016/j.heliyon.2023.e13508.